logo-loader
viewAchillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals receives key US patent for Hep C drug

drug_research_350_4d80c45f3018c.jpg

Drug developer Achillion Pharmaceuticals (NASDAQ:ACHN) said Wednesday that it has received a US patent for ACH-1625, an investigational drug designed to treat the hepatitis C virus.

The new patent, which covers composition of matter and method of use, has a term until 2029, the company said.

"This key patent grant provides a cornerstone for Achillion's intellectual property portfolio for ACH-1625 and a number of structurally related compounds," said president and CEO Michael D. Kishbauch.

The company is expecting phase 2 clinical trial results for ACH-1625 in the next months, and is also planning to move two other compounds into phase 1 trials during the first half of the year.

Quick facts: Achillion Pharmaceuticals, Inc.

Price: 6.76 USD

NASDAQ:ACHN
Market: NASDAQ
Market Cap: $947.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator's Stephen Blyth outlines five-year growth plans as core businesses...

Xpediator PLC's (LON:XPD) Stephen Blyth speaks to Proactive London following the release of its 2019 trading update. The firm saw turnover rise 19% to £212mln - boosted by acquisitions and organic growth while adjusted pre-tax profit's expected to be slightly above £5mln. Blyth says a big...

2 days, 18 hours ago

2 min read